Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study

被引:34
作者
Johnson, PWM
Swinbank, K
MacLennan, S
Colomer, D
Debuire, B
Diss, T
Gabert, J
Gupta, RK
Haynes, A
Kneba, M
Lee, MS
Macintyre, E
Mensink, E
Moos, M
Morgan, GJ
Neri, A
Johnson, A
Reato, G
Salles, G
van 't Veer, MB
Zehnder, JL
Zucca, E
Selby, PJ
Cotter, FE
机构
[1] St Jamess Univ Hosp, Imperial Canc Res Fund, Canc Med Res Unit, Leeds, W Yorkshire, England
[2] Natl Blood Serv, Leeds, W Yorkshire, England
[3] Hosp Clin, Hematopathol Sect, Barcelona, Spain
[4] Hop Paul Brousse, Serv Biochim, Villejuif, France
[5] UCL, Sch Med, Dept Histopathol, London, England
[6] Inst J Paoli I Calmettes, Hematol Lab, F-13009 Marseille, France
[7] Med Coll St Bartholomews, London, England
[8] City Hosp, Mol Diagnost Lab, Nottingham NG5 1PB, England
[9] Univ Hosp, Dept Hematol & Oncol, Gottingen, Germany
[10] Univ Texas, MD Anderson Canc Ctr, Div Lab Med, Houston, TX USA
[11] Hop Necker Enfants Malad, Hematol Lab, Paris, France
[12] Univ Nijmegen Hosp, Cent Hematol Lab, NL-6500 HB Nijmegen, Netherlands
[13] Univ Heidelberg, Med Ploiklin Geb 18A, Heidelberg, Germany
[14] Leeds Gen Infirm, HMDS, Leeds, W Yorkshire, England
[15] Ctr G Marcona, Serv Ematol Diagnost, Milan, Italy
[16] Univ Lund Hosp, Dept Oncol, S-22185 Lund, Sweden
[17] Univ Turin, Dipartimento Sci Biomed & Oncol Umana, Turin, Italy
[18] Ctr Hosp Lyon Sud, Dept Haematol, F-69310 Pierre Benite, France
[19] Dr Daniel Den Hoed Canc Ctr, Cell Separat Lab, NL-3008 AE Rotterdam, Netherlands
[20] Stanford Univ, Med Ctr, Mol Diagnost Lab, Stanford, CA 94305 USA
[21] Oncol Inst So Switzerland, Div Med Oncol, Bellinzona, Switzerland
[22] Inst Child Hlth, London, England
关键词
lymphoma; minimal residual disease; molecular diagnosis; polymerase chain reaction;
D O I
10.1023/A:1008385924543
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The capacity of the polymerase chain reaction (PCR) to detect very low numbers of cells bearing a t(14;18) translocation has led to its application in assessment of the results of treatment for follicular lymphoma, and suggestions that therapy might be guided by molecular studies. To test the reliability of PCR a collaborative study was undertaken to compare results from different laboratories in Europe and North America. Methods: Twenty laboratories with records of publication in molecular diagnostics were sent blood from normal donors with varying numbers of t(14;18)-bearing cells added from a cell line with a translocation in the major breakpoint region (MBR) of the bcl-2 gene. Samples contained 1000, 100, 10, 1 or 0 cells per ml of whole blood and were sent blinded in duplicate. PCR methodology varied widely, with the total number of amplification cycles between 30 and 70, and 13 different primers used for the MBR region. Twelve laboratories used nested PCR and eight single round amplification. Results: The sensitivity of nested and single round PCR was similar at 100 cells/ml but below this the nested method proved significantly more sensitive. The false positive rate was 28%, with 11 samples from 9 laboratories reported as positive when no t(14;18) cells were added. PCR product size and sequence analysis showed that false positives were due to contamination from cell-line DNA rather than background translocations in the donors. There was no significant difference in false positive rates between nested and single round techniques. Conclusion: The polymerase chain reaction to detectbcl-2-IgH rearrangements is presently carried out with widely disparate results. Further effort is required to bring forward a standard PCR protocol which can be re-tested in different laboratories to improve accuracy and reproducibility. The application of quantitative techniques such as real-time PCR may resolve many of the problems presently encountered.
引用
收藏
页码:1349 / 1354
页数:6
相关论文
共 16 条
  • [1] ASTER JC, 1992, AM J PATHOL, V141, P291
  • [2] COTTER F, 1990, BLOOD, V76, P131
  • [3] PERSISTENCE OF CIRCULATING T(14-18)-POSITIVE CELLS IN LONG-TERM REMISSION AFTER RADIATION-THERAPY FOR LOCALIZED-STAGE FOLLICULAR LYMPHOMA
    FINKE, J
    SLANINA, J
    LANGE, W
    DOLKEN, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (09) : 1668 - 1673
  • [4] GRIBBEN JG, 1993, BLOOD, V81, P3449
  • [5] GRIBBEN JG, 1991, BLOOD, V78, P3275
  • [6] IMMUNOLOGICAL PURGING OF MARROW ASSESSED BY PCR BEFORE AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR B-CELL LYMPHOMA
    GRIBBEN, JG
    FREEDMAN, AS
    NEUBERG, D
    ROY, DC
    BLAKE, KW
    WOO, SD
    GROSSBARD, ML
    RABINOWE, SN
    CORAL, F
    FREEMAN, GJ
    RITZ, J
    NADLER, LM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (22) : 1525 - 1533
  • [7] SIGNIFICANCE OF MOLECULAR MARKER-POSITIVE CELLS AFTER AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION FOR NON-HODGKINS-LYMPHOMA
    HARDINGHAM, JE
    KOTASEK, D
    SAGE, RE
    GOOLEY, LT
    MI, JX
    DOBROVIC, A
    NORMAN, JE
    BOLTON, AE
    DALE, BM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (05) : 1073 - 1079
  • [8] HIGHUCHI R, 1993, BIOTECHNOLOGY, V11, P1026
  • [9] DETECTION OF SPECIFIC POLYMERASE CHAIN-REACTION PRODUCT BY UTILIZING THE 5'-]3' EXONUCLEASE ACTIVITY OF THERMUS-AQUATICUS DNA-POLYMERASE
    HOLLAND, PM
    ABRAMSON, RD
    WATSON, R
    GELFAND, DH
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (16) : 7276 - 7280
  • [10] DETECTION OF CELLS BEARING THE T(1418) TRANSLOCATION FOLLOWING MYELOABLATIVE TREATMENT AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR FOLLICULAR LYMPHOMA
    JOHNSON, PWM
    PRICE, CGA
    SMITH, T
    COTTER, FE
    MEERABUX, J
    ROHATINER, AZS
    YOUNG, BD
    LISTER, TA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (04) : 798 - 805